Remdesivir shows success in large COVID-19 trial

The drug remdesivir significantly reduces the time it takes for COVID-19 patients to recover, as compared with a placebo treatment, according to a large, international study.

Remdesivir shows success in large COVID-19 trial

Speaking during an interview, Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases (NIAID), said, “the data shows that remdesivir has a clear-cut, significant, positive effect in diminishing the time to recovery”.

He said that although a 31% improvement doesn’t seem like a knockout 100%, it is a very important proof of concept.
“What it has proven is that a drug can block this virus”, Fauci said.
The NIAID-sponsored trial began on Feb. 21 and included “about 1,090 plus” participants from various sites around the world, including the U.S., Germany,.

Denmark, Spain, Greece and the U.K
In addition to recovering more quickly, on average, fewer people in the remdesivir group than the placebo group died, though the result wasn’t statistically significant. Follow us on Google newsTwitter and on Facebook

0/Post a Comment/Comments

Previous Post Next Post